• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Public Health

FDA-regulated clinical trials rarely report violations

byAnees DaudandJames Jiang
February 11, 2015
in Public Health
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. This study, which identified clinical trials that the FDA deemed to have committed significant violations, determined that fewer than 5% of the publications that resulted from these trials actually mentioned committing violations, even though three-fourths of them received the results of the inspection before the publication date.

2. The most common types of violations included failure to follow the investigational plan, inadequate recordkeeping, issues with patient safety, rights, and welfare.

Evidence Rating Level: 3 (Fair)          

Study Rundown: The Food and Drug Administration is involved in regularly inspecting clinical trials to ensure that the investigators followed good clinical practices throughout their research. However, in cases where significant violations are identified, the FDA and the investigational group often does not make that readily available to the larger scientific community. This study, which identified clinical trials that the FDA deemed to have committed significant violations, was carried out to determine the nature of those violations and whether they were acknowledged. Of the articles that arose from trials that had significant violations, fewer than 5% actually mentioned committing those violations, even though three-fourths of them received the results of the inspection before the publication date. The most common types of violations included failure to follow the investigational plan, inadequate recordkeeping, issues with patient safety, rights, and welfare.

The strength of the study was that the investigators highlighted the types of violations committed by the trials, and that they focused only on the most severe types of violations. The weakness of the study include the fact that not all of trials were likely included since the FDA database is not up to date, and the fact that only trials from one point in time were included. This study does, however, encourage future investigations into this important topic.

Click to read the study, published today in JAMA Internal Medicine

Relevant Reading: Analysis of warning letters issued by the US Food and Drug Administration to clinical investigators, institutional review boards and sponsors: a retrospective study

RELATED REPORTS

Estimated costs of clinical trials for FDA approval of novel therapeutics

Inconsistent quality of evidence for biomarker use on FDA drug labels

Effectiveness of medical device postapproval surveillance unclear

In-Depth [cross-sectional study]: Clinical trials that were deemed by the FDA to have significant violations (entitiled “official action indicated”, or OAI) were searched in the FDA database in July 2012. This search was supplemented by Google searches of the FDA.gov domain. Additionally, all warning letters issued to a clinical investigator were reviewed as well. A total of 421 OAI-rated inspections were found using these methods. These documents were reviewed, and when a clinical trial was identified, the literature was searched for any resultant publications.

In the final analysis, 57 trials, resulting in 78 published articles in peer-reviewed journals, were included. Of these articles, only 3 (4%) mentioned the violations determined by the FDA, even though 59 of the 78 articles (76%) received the results of the inspection at least six months before the publication date. The types of violations most commonly noted were falsification of information (39%), problems with adverse events reporting (25%), failure to follow the investigational plan (74%), inadequate recordkeeping (61%), failure to protect patient safety, rights, and welfare (53%), and other violations (20%).

Image: PD

©2015 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: FDA
Previous Post

Dietary recommendations on fat intake based on limited evidence

Next Post

JAK2 and TET2 mutations temporally linked with myeloproliferative disorder outcomes

RelatedReports

Chronic Disease

Estimated costs of clinical trials for FDA approval of novel therapeutics

September 28, 2018
Oral contraceptive pills associated with reduction in ovarian cancer incidence
Public Health

Inconsistent quality of evidence for biomarker use on FDA drug labels

October 14, 2014
Novel biodegradable sirolimus-eluting stents non-inferior to durable everolimus-eluting stents [BIOSCIENCE trial]
Public Health

Effectiveness of medical device postapproval surveillance unclear

September 30, 2014
Pre-operative transcranial magnetic stimulation useful for language mapping
Chronic Disease

Atypical antipsychotics linked with acute kidney injury in the elderly

August 19, 2014
Next Post
JAK2 and TET2 mutations temporally linked with myeloproliferative disorder outcomes

JAK2 and TET2 mutations temporally linked with myeloproliferative disorder outcomes

Unemployment linked to increased risk of suicide

Unemployment linked to increased risk of suicide

Use of injectable contraceptive, Depo-Provera, linked to increased risk of HIV

HIV-positive-to-HIV-positive kidney transplantation successful at 5 years

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Treatment of anal high-grade squamous intraepithelial lesions can reduce rates of progression to invasive anal cancer.
  • High tumour mutation burden in NSCLC associated with improved clinical outcomes of PD-L1 blockade across PD-L1 expression subgroups
  • Subsidization of supermarkets may help reduce obesity risk in children
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.